Rhythm Pharmaceuticals is tackling rare genetic obesity disorders with their MC4R agonist, Setmelanotide. They have 3 upcoming catalysts, the most important being the effect of the compound on a basket of high impact “loss of function” patients (POMC/LEPR-deficient heterozygotes, in particular). I go through all their catalysts in great detail along with a mock model. Biogen’s Aducanumab was decidedly voted against in a recent FDA advisory committee with regards to the evidence provided in support of an effect in Alzheimer’s disease. The stock saw serious volatility after the FDA briefing documents were released, but has since subsided with a CRL likely being priced in. I also touch on $AXGT ($SIOX) and $ATNM.
If you want to help out the show (or join the discord), take a look at my patreon: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire Send me an email firstname.lastname@example.org://www.breakingbiotech.com #breakingbiotech Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
BioXcel (#BTAI) is a clinical-stage biotechnology company looking to commercialize neuroscience and oncology products developed with the help of their unique AI technology. I go through the data they have seen to date and upcoming catalysts that are likely to significantly affect the stock in the short term. As well, I touch on Cassava Sciences’ update on PTI-125 and an interesting coincidence regarding the structure of the molecule. Credit goes to twitter user: @NoseRubInvest for finding this! Finally, I touch on updates from $TRVN, $NVAX and $TGTX.
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
Cassava Sciences is a neuroscience company with a focus on Alzheimer’s disease. Their lead compound, PTI-125, is able to bind to a scaffold protein that is critical in mediating the hyperphosphorylation of Tau by Aβ. The hope is that treatment of PTI-125 will reduce Tau hyperphosphorylation and prevent the negative effects associated with Alzheimer’s disease.
In this video, I talk about Alzheimer’s disease and how PTI-125 might play a role in helping patients. I talk about #SAVA and their latest Phase 2A trial with some predictions on their upcoming Phase 2B data (to be released soon). Then, I finish the video with a quick 2019 portfolio wrap up.
Follow me on twitter @matthewlepoire
Email me at email@example.com
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.
Biogen/Eisai to present updated subgroup analyses on their Phase 2 study looking at their Alzheimer’s medicine, BAN2401. This antibody binds to amyloid beta protofibrils, reducing plaques in the brain. In this video, I go through Biogen’s original data and talk about the problems parsing the Apoe E4+ patients.
The options market is pricing in a 22 pt move in the stock by Oct 26th.
This morning, Axovant announced that Intepirdine failed to meet both primary objectives in the Mindset trial. The press release said,
“After 24 weeks of treatment, change from baseline in cognition was non-significantly improved in the intepirdine arm versus the placebo arm (0.36 ADAS-Cog points; p-value = 0.22). In addition, there was essentially no difference between the intepirdine and placebo arms in change from baseline in activities of daily living (0.09 ADCS-ADL points; p-value = 0.83).”
An improvement of only 0.36 in ADAS-Cog score is substantially lower than the 1.5 improvement that they saw in the Phase II trial (Maher-Edwards G, 2015). What we can assume from this is that the Donepezil control group was substantially more “Donepezil-responsive” than in the Phase II Donepezil group or the combination treatment was just ineffective.
I think the only way this trial could have been a success is if Axovant was more specific in their inclusion criteria. They really needed a group of patients that were losing Donepezil effectiveness (~6 months or more of chronic Donepezil treatment) so that they could maximize the contribution of Intepirdine (if there is efficacy). It still isn’t known whether the combination of 5-HT6 antagonism and acetylcholinesterase inhibition increases human brain acetylcholine more than just acetylcholinesterase inhibition alone. It also isn’t known whether there is a max functional improvement from increased brain acetylcholine, whereby any further increase does not produce functional improvements. These questions are difficult to answer, given the obvious lack of human brain samples for study.
It is disappointing that the trial failed, but I was able to cover my short position this morning and make a 70% return.
AXON’s low of the day was $6.13, so those who sold volatility instead of picking a direction did very well, given the move was less than expected (see my original post). Long-term, the company has other ongoing trials for both Intepirdine and Nelotanserin, which definitely have clinical potential in other diseases. For Alzheimer’s though, it may be wise to look towards other targets. There is still a large unmet need in Alzheimer’s, and the company that takes the risk and succeeds will be rewarded handsomely by the market.
The first company I’m going to dive into is Axovant Sciences Ltd. Results from their upcoming phase 3 clinical trial, called Mindset, will lead to a big move in the company’s stock. This trial is evaluating the effects of the 5-HT6 receptor antagonist, Intepirdine, in combination with Donepezil on Alzheimer’s Disease (AD). As of last Friday, options are pricing in a move of ~$24 before the end of 10-2017, so it’s worth investigating if this event is worth attempting to profit from. Results are expected before the end of 09-2017.
AD drug trials have largely been met with disappointment with the exception of some acetylcholinesterase inhibitors (Donepezil, etc) and a NMDA receptor AD antagonist (Memantine). The reasons for this are numerous, but it also stands to reason that the FDA has an interest in approving a new AD drug, if one shows good efficacy.
One of the hallmarks of AD is reduced cholinergic neurons in the brain. This is associated with the dementia symptoms like loss of memory, therefore, the development of safe acetylcholinesterase inhibitors is a direction many drug companies went. Turns out these drugs increase acetylecholine and improve symptoms without reducing the actual progress of the AD. This brings us to the 5-HT6 receptor.
5-HT receptors are serotonin receptors, but happen to increase acetylcholine when they are antagonized. This led researchers to postulate that acetylcholine could be increased in AD patients and improve the symptomology, which Donepezil does. However, most 5-HT6 receptor antagonists by themselves were ineffective at treating AD symptoms to a significant degree (Maher-Edwards G, 2010, Maher-Edwards G, 2011, Maher-Edwards G, 2015). When combined with Donepezil, however, there is preliminary data suggesting that this synergy could increase brain acetylcholine more than each could by themselves, demonstrated in rodents (Fig. 1. adapted from Dawson, LA, 2011, compare the purple line to the red line). This is the working theory behind the effectiveness in the phase II trial that prompted Axovant to conduct phase III clinical studies (Maher-Edwards G, 2015).
Fig. 1. Effects of SB-742457, Donepezil or their combination on brain acetylecholine. Note that Intepirdine is the same as SB-742457, which is the same as RVT-101. Keep in mind this is data only suggests a short-term effect and I haven’t found any data on long-term brain acetylcholine levels with treatment of Donepezil and Intepirdine.
The Mindset clinical trial (NCT02585934) has two primary outcome measures. Change from baseline on the (1) ADAS-Cog-11 scale and (2) ADCS-ADL scale. Both these scales are commonly used in clinical studies to analyze patient’s cognitive and non-cognitive brain function and both will need to show a statistical significance in order for the FDA to approve this drug. The researchers are comparing RVT-101 (Intepirdine) plus two different doses of Donepezil (5mg/day and 10mg/day) to only Donepezil at those doses. This splits the 1315 patients into 4 groups, lowering the power of the analyses than if they only had two groups (i.e. RVT-101 + 10mg Donepezil vs 10mg Donepezil). This also increases their chance of seeing a positive effect, since the 5mg Donepezil dose leaves much more room for the potential acetylcholine-boosting effects of RVT-101 to improve the primary endpoints of the trial.
Burns et al. evaluated long-term Donepezil treatment in a group similar to those in the Mindset trial and saw that 5mg/day Donepezil led to a substantial improvement in ADAS-Cog scores that drifted towards placebo by 24 weeks, whereas the 10mg/day group still had significant benefits from the treatment (Fig 2. adapted from Burns A, 1999).
Fig. 2. Mean change from baseline (+/- SEM) of ADAS-cog scores in patients receiving 5 and 10mg/day Donepezil and placebo groups.
Patients in the Mindset trial will be somewhere in the treatment regimen of Donepezil (the phase II study had them on a stable dose for 2 months with the first dose given at least 6 months before RVT-101 treatment, Maher-Edwards G, 2015). This leaves the potential of Intepirdine to come in and improve ADAS-Cog-11 and ADCS-ADL at the 24 week time frame. Some confusion will arise if RVT-101 + 5mg Donepezil leads to significant improvement compared to 5mg Donepezil, but not compared to only 10mg Donepezil, since the max benefits could be achieved by providing only one drug. I would argue giving only one drug is better if you don’t get a better response with two, despite the higher dose. Also, when Donepezil is ramped up from 5mg/day to 10mg/day after 4-6 weeks, the cholinergic adverse events are no different than placebo (Burns A, 1999).
Given everything above, here are my overall suspicions on the Mindset trial:
The chance that the data from the phase II trial will to be fully reproduced is low (Fig. 3. adapted from Maher-Edwards G, 2015).
Fig. 3. Summaries of Study 1 (SB742457 monotherapy) and Study 2 (SB742457, Donepezil cotreatment from Maher-Edwards G, 2015.
Study 1 shows an insignificant effect of donepezil on ADAS-Cog compared to placebo (p=0.821). We would expect that Donepezil treatment leads to a significant improvement in those time points, shown reproducibly in many previous studies. This is not directly relevant because Study 2 is the design of Mindset, but it’s worth noting because something with this cohort is not representative of the greater population.
Study 2 shows that the placebo group (Donepezil) gets worse by +1.2 points on the ADAS-Cog scale after 24 weeks (blue box). If we assume the patients had been on Donepezil for months, we would expect a drop in ADAS-Cog of ~0.5 as we see in Burns A. 1999. SB742457 35mg + Donepezil improves ADAS-Cog compared to placebo by -1.5 compared to a group worsening in their disease. This is problematic because if this cohort of people happens to have less Donepezil effectiveness compared to the greater population, a larger study will see a greater effect of Donepezil, leading to a smaller difference between RVT-101 + Donepezil.
2. Previous drugs with the same mechanism as Intepirdine failed numerous phase III clinical trials.
Idalopirdine is a 5-HT6 receptor inhibitor that was brought to multiple phase III trials by Lundbeck for its effectiveness in AD in combination with Donepezil. All the trials failed, and sadly we don’t have the publications to investigate deeper.
The CEO of Axovant, David Hung, gave an interview with someone from Morgan Stanley. In regards to the upcoming trial, Hung was asked about Lundbeck’s phase III attempts with Idalopirdine. He said that the reason for the failure is due to Lundbeck changing the Idalopirdine dosing from their phase II dosing of 3 times daily (TID) regimen to once daily in their phase III. The once daily dose was higher than the TID dose, so even with a 10-hour half-life, a substantial blood concentration would be present most of the day so I don’t find this argument compelling.
3. GSK was not interested in pursuing RVT-101 further.
This is a smaller point, but one that should be addressed. There are many reasons why GSK may not have been interested in taking RVT-101 to phase III. Among those, we can assume that the risk-reward of doing so was not enticing enough.
The prior probability that this trial is a success is 1:1. Looking at clinical trial success data, we see that an average neurological disease phase III clinical trial is a success 58.1% of the time (Clinical Development Success Rates, 2006-2015). If we assign subjective but educated values to the independent claims I make above, the likelihood that the trial succeeds given Suspicion 1 is about 3:5. I give Suspicion 2 a ratio of 1:4 and Suspicion 3 a ratio of 0.99:1. I think these are generous enough, given the data. Multiplying this out leads to a 13% chance that the trial succeeds.
Together, this makes me confident in a short position. A look at the IV of Oct options shows around 400% which means that options prices are greatly inflated. This is an argument for selling premium, but then a look at the bid-ask spread is dissuading since they are all over >0.5. Given this, I’m going to short equity and aim to profit off a drop in the stock price.
So far, the position is down ~6% since AXON has had a nice run-up this past week. I’m going to hold and cover after the news is released in a week or so.
Axovant Sciences’ (AXON) CEO David Hung Presents at Morgan Stanley 15th Annual Global Healthcare Brokers Conference (Transcript)
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord. 1999.
Dawson LA. Pharmacology of 5-HT6 receptors, Part II. International Review of Neurobiology. 1st Edition. Borsini F. 2011.
Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011.
Maher-Edwards G, Waston, C, Ascher J, Barnett C, Boswell D, Davies J, Fernandez M, Kurz A, Zanetti O, Safirstein B, Schronen JP, Zvartau-Hind M, Gold M. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer’s disease. Alz Dem: Trans Res Clin Int. 2015.
Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, Davy M, Williams P. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease. Curr Alzheimer Res. 2010.